Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
ACTIVE_NOT_RECRUITING
Status
Conditions
- Advanced Malignant Solid Neoplasm
- Malignant Solid Neoplasm
- Recurrent Ependymoma
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Hepatoblastoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Glioma
- Recurrent Malignant Solid Neoplasm
- Recurrent Medulloblastoma
- Recurrent Neuroblastoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Osteosarcoma
- Recurrent Primary Central Nervous System Neoplasm
- Recurrent Rhabdoid Tumor
- Recurrent Rhabdomyosarcoma
- Recurrent Soft Tissue Sarcoma
- Refractory Ependymoma
- Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Refractory Hepatoblastoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Glioma
- Refractory Malignant Solid Neoplasm
- Refractory Medulloblastoma
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Osteosarcoma
- Refractory Primary Central Nervous System Neoplasm
- Refractory Rhabdoid Tumor
- Refractory Rhabdomyosarcoma
- Refractory Soft Tissue Sarcoma
- Wilms Tumor
Interventions
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Bone Marrow Aspiration and Biopsy
- PROCEDURE: Bone Scan
- PROCEDURE: Computed Tomography
- DRUG: Ensartinib
- OTHER: Laboratory Biomarker Analysis
- PROCEDURE: Magnetic Resonance Imaging
- OTHER: Pharmacological Study
- PROCEDURE: Positron Emission Tomography
- PROCEDURE: Radionuclide Imaging
- PROCEDURE: X-Ray Imaging
Sponsor
National Cancer Institute (NCI)
Collaborators